二氢吡啶类钙通道受体拮抗剂代谢及受体相关基因的研究进展  

Research Progress in Metabolism and Receptor Gene of Dihydropyridines Calcium Channel Antagonists

作　　者：蔡菁菁[1] 黄志军[1] 袁洪[1] 

机构地区：[1]中南大学湘雅三医院临床药理中心,长沙410013

出　　处：《医学综述》2010年第24期3705-3707,共3页Medical Recapitulate

摘　　要：二氢吡啶类钙通道受体拮抗剂为我国普遍使用的治疗高血压的一线药物,但其单一降压有效率仅在50%左右,既往大量研究均显示,遗传背景的差异是造成药物疗效差异的主要因素之一。现拟从药物代谢酶CYP3A、转运体MDR1及钙通道受体CACNA1C等方面阐述其基因多态性对此类钙离子通道拮抗剂代谢、分布和疗效的影响,从而指导高血压的个体化用药及减少药物不良反应的发生。Dihydropyridine calcium channel antagonist is the first-line antihypertensive drug in China.The effectiveness rate of dihydropyridines monotherapy is just 50%.Increasing evidence supports that the major problem of low efficacy of hypertensive therapy is mostly due to the heterogeneity in genetic background.This review summarizes the effects of CYP3A,MDR1,CACNA1C polymorphisms on metabolism,disposition,and efficacy of dihydropyridines.Genotype-guided,personalized medication is emerging in the mainstream medicine to increase drug efficacy and safety.

关 键 词：钙通道受体拮抗剂 二氢吡啶类 基因多态性 

分 类 号：R394.6[医药卫生—医学遗传学]